Sionna Therapeutics (NASDAQ:SION) Trading Down 4.5% – Should You Sell?

Sionna Therapeutics, Inc. (NASDAQ:SION) dropped 4.5% during mid-day trading on Monday . The stock traded as low as $47.53 and last traded at $47.1790. Approximately 37,710 shares traded hands during trading, a decline of 90% from the average daily volume of 379,349 shares. The stock had previously closed at $49.41.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on SION shares. Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Citizens Jmp restated a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Stifel Nicolaus increased their price target on Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a report on Monday, May 18th. Wedbush started coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price objective on the stock. Finally, JonesTrading boosted their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Trading Down 6.1%

The firm’s fifty day simple moving average is $40.74 and its two-hundred day simple moving average is $39.61. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -24.03 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, analysts forecast that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insider Activity at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 184,639 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the transaction, the director owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. This represents a 6.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the transaction, the director owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 989,630 shares of company stock valued at $44,987,483 over the last quarter. 5.10% of the stock is currently owned by company insiders.

Institutional Trading of Sionna Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. purchased a new stake in Sionna Therapeutics in the 3rd quarter valued at about $30,000. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics during the second quarter worth about $31,000. GF Fund Management CO. LTD. acquired a new stake in shares of Sionna Therapeutics during the fourth quarter valued at about $36,000. Balyasny Asset Management L.P. acquired a new stake in shares of Sionna Therapeutics during the fourth quarter valued at about $58,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sionna Therapeutics in the 4th quarter valued at approximately $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.